Long Term Commitments: Novo Breaks New Ground with Victoza.
This article was originally published in RPM Report
The Victoza approval took longer than Novo hoped. But the review time looks like nothing compared to the post-marketing monitoring the company will be required to do.
You may also be interested in...
US government alleged sales reps gave information to physicians to create a false or misleading impression that Victoza's boxed warning and REMS messages about medullary thyroid cancer were 'erroneous, irrelevant or unimportant.' Novo's $59m settlement includes resolution of whistleblower lawsuits alleging off-label marketing.
The second year of the FDAAA-era is over, and FDA is using its new drug safety tools (Risk Evaluation & Mitigation Strategies and mandatory post-marketing studies) more often. Not only are more drugs requiring REMS and mandatory trials, the burden of those programs is increasing.
There are new considerations for developing diabetes drugs when it comes to FDA's expectations. Here are some of the questions to consider.